Patients (total number) | Gender (male/female) | Age (Years) | Disease duration (years) | RF (+/−) | ESR (mm/1 hour) | CRPa(mg/l) | Number of ARA-criteria (RA) | Concomitant medication (n) |
---|---|---|---|---|---|---|---|---|
Control group | Â | Â | Â | Â | Â | Â | Â | Â |
(n = 20) | 15/5 | 54.7 ± 4.0 | 0.3 ± 0.3b | n.d. | n.d. | n.d. | n.a. | NSAIDs (n = 1) |
 |  |  | (n.d. = 13) |  |  |  |  | None (n = 7) |
 |  |  |  |  |  |  |  | (n.d. = 12) |
Osteoarthritis | Â | Â | Â | Â | Â | Â | Â | Â |
(n = 26) | 4/22 | 71.0 ± 1.4 | 7.0 ± 1.3 | 3/18 | 22.4 ± 2.7 | 5.3 ± 1.5 | 0.2 ± 0.1 | NSAIDs (n = 16) |
 |  |  | (n.d. = 1) | (n.d. = 5) | (n.d. = 5) | (n.d. = 3) |  | None (n = 10) |
Rheumatoid arthritis | Â | Â | Â | Â | Â | Â | Â | Â |
(n = 33) | 8/25 | 57.0 ± 2.7 | 12.5 ± 2.0 | 21/7 | 42.7 ± 4.5 | 21.4 ± 4.1 | 5.2 ± 0.3 | Prednisolone (n = 23) |
 |  |  |  | (n.d. = 7) | (n.d. = 10) | (n.d. = 3) |  | Methotrexate (n = 18) |
 |  |  |  |  |  |  |  | Sulfasalazine (n = 5) |
Chloroquine (n = 2) | ||||||||
Leflunomide (n = 2) | ||||||||
Cyclosporine (n = 1) | ||||||||
Gold (n = 1) | ||||||||
NSAIDs (n = 22) |